Newsfeeds - Spark Newswire

2 minute read

Incyte Reports Acceptance, Priority Review For Supplemental New Drug Application For Ruxolitinib Cream As Treatment For Patients With Vitiligo

Today, 4:46 AM

Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical

INCY

1 minute read

Why Are Datadog, Zscaler, Airbnb, Fortinet, Lucid Trading Higher Premarket?

By Anusuya Lahiri

Today, 4:46 AM

Airbnb, Inc (NASDAQ:ABNB), Fortinet, Inc (NASDAQ:FTNT), Palo Alto Networks, Inc (NASDAQ:PANW), Lucid Group, Inc (NASDAQ:LCID), Zscaler, Inc (NASDAQ:ZS),…

ABNB

3 minute read

MorphoSys and Incyte Announced Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma at ASH; Said Results Indicate…

By Charles Gross

Today, 4:46 AM

MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (NASDAQ: MOR), and Incyte (NASDAQ: INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi®) in combination with lenalidomide agains

INCY

2 minute read

Events
News

Incyte Announced Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas at ASH 2021

By Charles Gross

Today, 4:46 AM

Incyte (Nasdaq: INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), for the treatment of patients with relapsed or refractory follicular lymphoma (FL) (CITADEL-203)

INCY

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Wednesday, Dec. 1, 2021: SHOP, IOVA, REGN, CDXS, INCY, COIN, OPEN, AMZN, LMT

By Benzinga Newsdesk

Today, 4:46 AM

SHOPIFY INC (SHOP) - 34151 IOVANCE BIOTHERAPEUTICS INC (IOVA) - 42230 REGENERON PHARMACEUTICALS INC (REGN) - 6460 CODEXIS INC (CDXS) - 121400 INCYTE CORP (INCY) - 187064 COINBASE GLOBAL INC (COIN) -

AMZN

1 minute read

BMO Capital Initiates Coverage On Incyte with Market Perform Rating, Announces Price Target of $75

By Benzinga Newsdesk

Today, 4:46 AM

BMO Capital analyst Evan Seigerman initiates coverage on Incyte (NASDAQ:INCY) with a Market Perform rating and announces Price Target of $75.

INCY

1 minute read

Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $109

By Benzinga Newsdesk

Today, 4:46 AM

Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $110 to $109.

INCY

1 minute read

Incyte Stock Falls Despite Q3 Earnings Beat Street View

By Vandana Singh

Today, 4:46 AM

Incyte Corporation’s (NASDAQ:INCY) Q3 adjusted EPS reached $1.18, compared to $0.23 posted a year ago, beating the consensus of $0.73. …

INCY

4 minute read

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US

By Shanthi Rexaline

Today, 4:46 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AADI

1 minute read

Incyte Q3 Adj. EPS $1.18 Beats $0.73 Estimate, Sales $812.99M Beat $738.77M Estimate

By Benzinga Newsdesk

Today, 4:46 AM

Incyte (NASDAQ:INCY) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $0.73 by 61.64 percent. This is a 413.04 percent increase over earnings of $0.23 per share from the same

INCY